{"commentary":{"count":30,"free_build_floor":8,"listing_floor":3,"by_channel":{"podcast":12,"youtube":11,"x_thread":7},"note":"Indexed podcasts, YouTube videos and X posts that name this trial. A report screens them, searches for more and cites what clinicians said when it is built."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT04752059\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's public preview; the full report is still bought."},"name":"TUXEDO-1","nct_id":"NCT04752059","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=tuxedo-1-nct04752059. The price is fixed at order. We build the report after the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1250,"size":"standard","size_rule":"Standard: 13–40 commentary sources"},"registry":{"acronym":"TUXEDO-1","arms":[{"description":"Single arm phase II trial","label":"T-DXd 5.4 mg","type":"EXPERIMENTAL"}],"collaborators":["Daiichi Sankyo"],"completion_date":{"date":"2023-05-01","type":"ACTUAL"},"conditions":["Breast Cancer Stage IV"],"enrollment":{"count":15,"type":"ACTUAL"},"has_results":false,"interventions":[{"name":"Trastuzumab deruxtecan","type":"DRUG"}],"last_update":"2023-05-12","lead_sponsor":"Medical University of Vienna","official_title":"Phase II Study of Trastuzumab-Deruxtecan (T-DX; DS-8201a) in HER2-positive Breast Cancer Patients With Newly Diagnosed or Progressing Brain Metastases","overall_status":"COMPLETED","phases":["PHASE2"],"primary_completion_date":{"date":"2023-05-01","type":"ACTUAL"},"primary_outcomes":[{"measure":"Reponse rate of brain metastases to trastuzumab-deruxtecan","timeFrame":"From date of randomization until the date of first documented progression or date of death from any cause or treatment discontinuation from any other reason, whichever came first, assessed up to 36 months"}],"references":[{"citation":"Bartsch R, Berghoff AS, Furtner J, Marhold M, Bergen ES, Roider-Schur S, Starzer AM, Forstner H, Rottenmanner B, Dieckmann K, Bago-Horvath Z, Haslacher H, Widhalm G, Ilhan-Mutlu A, Minichsdorfer C, Fuereder T, Szekeres T, Oehler L, Gruenberger B, Singer CF, Weltermann A, Puhr R, Preusser M. Trastuzumab deruxtecan in HER2-positive breast cancer with brain metastases: a single-arm, phase 2 trial. Nat Med. 2022 Sep;28(9):1840-1847. doi: 10.1038/s41591-022-01935-8. Epub 2022 Aug 8.","pmid":"35941372","type":"RESULT"}],"start_date":{"date":"2020-07-28","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Phase II Study of T-DX in HER2-positive Breast Cancer Brain Metastases","url":"https://clinicaltrials.gov/study/NCT04752059"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"2.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/tuxedo-1-nct04752059"}